Condition: Lung Transplant Infection · Lung Transplant; Complications · Lung Transplant Failure and Rejection · Sponsor: CareDx
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama (UAB) | Birmingham, Alabama, United States | — |
| St. Joseph's Hospital & Medical Center | Phoenix, Arizona, United States | — |
| Cedars Sinai Medical Center | Los Angeles, California, United States | — |
| University of California (UCSF) School of Medicine | San Francisco, California, United States | — |
| University of CO Anschutz Medical Campus | Aurora, Colorado, United States | — |
| AdventHealth Orlando | Orlando, Florida, United States | — |
| Loyola University Medical School | Maywood, Illinois, United States | — |
| University of Louisville Health | Louisville, Kentucky, United States | — |
| University of Mayland | Baltimore, Maryland, United States | — |
| Brigham and Womens Hospital | Boston, Massachusetts, United States | — |
| Washington University-Barnes Jewish Hospital | St Louis, Missouri, United States | — |
| NYU Langone Health | New York, New York, United States | — |
+ 10 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.